Valuation: Insmed Incorporated

Market Cap 31.69B 28.87B 26.73B 24.18B 45.36B 2,960B 47.47B 323B 128B 1,599B 119B 116B 5,066B P/E 2026 *
-89.5x
P/E 2027 * 207x
Enterprise Value 31.18B 28.41B 26.29B 23.78B 44.62B 2,912B 46.7B 318B 126B 1,573B 117B 115B 4,984B EV / Sales 2026 *
16.8x
EV / Sales 2027 * 10.3x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+20.58%
1 week+22.35%
Current month+28.32%
1 month+51.60%
3 months+10.56%
6 months+34.49%
Current year-17.00%
1 week 118
Extreme 118
149.07
1 month 92.62
Extreme 92.625
149.07
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
10/19/26 A Free

Director

6,139 0.0028%
10/19/26 A Free

Director

6,139 0.0028%
9/9/26 A Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+20.58%+22.35%-29.03%+482.03% 26.28B
+0.19%-3.96%+54.92%+69.15% 65.45B
-0.14%-3.20%+7.62%+89.74% 58.93B
+0.06%+0.15%+25.94%+87.89% 55.21B
-0.97%-3.91%+12.98%+113.88% 46.1B
-2.83%-7.58%+15.21%+22.34% 42.49B
+3.61%+2.63%+21.96%+46.39% 35.56B
-0.24%-9.59%+126.05%+647.44% 34.57B
+0.03%-0.93%+76.71%+57.74% 32.46B
-6.25%-11.81%+28.01%-14.12% 23.35B
Average +1.43%-3.64%+34.04%+160.25% 42B
Weighted average by Cap. +0.87%-3.22%+33.87%+140.60%

Financials

2026 *2027 *
Net sales 1.86B 1.7B 1.57B 1.42B 2.66B 174B 2.79B 18.97B 7.53B 93.93B 6.98B 6.84B 298B 2.99B 2.72B 2.52B 2.28B 4.28B 279B 4.48B 30.49B 12.09B 151B 11.22B 10.98B 478B
Net income -352M -320M -297M -268M -503M -32.83B -527M -3.58B -1.42B -17.74B -1.32B -1.29B -56.2B 164M 149M 138M 125M 234M 15.3B 245M 1.67B 662M 8.27B 615M 602M 26.19B
Net Debt -514M -469M -434M -392M -736M -48.05B -771M -5.24B -2.08B -25.96B -1.93B -1.89B -82.24B -949M -865M -800M -724M -1.36B -88.63B -1.42B -9.67B -3.84B -47.89B -3.56B -3.49B -152B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
19/11/26 $144.46 +20.58% 14,406,502
18/11/26 $119.80 -1.69% 1,944,159
17/11/26 $121.86 -0.83% 2,398,022
16/11/26 $122.88 +1.42% 2,233,188
13/11/26 $121.16 +2.62% 1,543,624
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
144.46USD
Average target price
194.18USD
Spread / Average Target
+34.42%
  1. Stock Market
  2. Stocks
  3. INSM Stock